Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Jul. 13, 2022, Moderna announced it has now demonstrated significantly higher antibody titers against all tested variants,…
On Jul. 13, 2022, Moderna announced it has now demonstrated significantly higher antibody titers against all tested variants,…
On Jul. 11, 2022, Novavax announced an agreement with the U.S. Department of Health and Human Services (HHS),…
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
On Jul. 8, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) confirmed the…
On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…
On Jul. 5, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
On Jul. 5, 2022, Tgen and Northern Arizona University announced that a research team found that the vaccine…
On Jul. 5, 2022, the National Institutes of Health and National Cancer Institute announced COVID-19 was the third…
On Jun. 29, 2022, Pfizer and BioNTech announced a new vaccine supply agreement with the U.S. government to…
On Jun. 28, 2022, the National Institutes of Health (NIH) announced that a Phase 1 clinical trial of…
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
On Jun. 24, 2022, Emergent BioSolutions announced that the U.S. Food and Drug Administration accepted for review the…
On Jun. 23, 2022, BioNTech announced it had has reached the next milestone in the establishment of scalable…
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Jun. 22, 2022, Merck announced that that the U.S. Food and Drug Administration (FDA) had approved an…
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
On Jan. 19, 2022, South African-born U.S. biotech billionaire Patrick Soon-Shiong launched a vaccine manufacturing plant in the…
On Jun. 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration (FDA) had granted emergency…
On Jun. 17, 2022, the U.S. Food and Drug Administration (FDA) authorized emergency use of the Moderna COVID-19…
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…
On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax…
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 2, 2022, The European Commission and the vaccine developer Moderna announced they have reached an agreement…
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…